Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No Graft Versus Host Disease (GvHD) Prophylaxis for Treatment of Advanced Hematologic Malignancies

Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies without the Use of Post-Transplant Cyclophosphamide

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Orca-T in Patients ≥ 55 Years Old with Hematologic Malignancies